Surmodics (NASDAQ:SRDX - Get Free Report)'s stock had its "hold" rating reaffirmed by analysts at Needham & Company LLC in a research report issued to clients and investors on Thursday,Benzinga reports.
Separately, StockNews.com initiated coverage on shares of Surmodics in a report on Thursday. They issued a "hold" rating for the company. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $50.00.
View Our Latest Analysis on Surmodics
Surmodics Price Performance
SRDX stock traded down $0.11 during mid-day trading on Thursday, hitting $38.38. 111,660 shares of the stock were exchanged, compared to its average volume of 230,604. The business has a fifty day moving average price of $38.62 and a 200 day moving average price of $38.60. The stock has a market capitalization of $547.57 million, a price-to-earnings ratio of -384.90 and a beta of 1.20. Surmodics has a 12 month low of $25.17 and a 12 month high of $42.44. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.22.
Hedge Funds Weigh In On Surmodics
A number of institutional investors and hedge funds have recently modified their holdings of SRDX. Vanguard Group Inc. boosted its stake in shares of Surmodics by 0.7% in the first quarter. Vanguard Group Inc. now owns 865,214 shares of the company's stock worth $25,385,000 after acquiring an additional 5,927 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Surmodics by 5.0% in the 2nd quarter. Renaissance Technologies LLC now owns 606,538 shares of the company's stock worth $25,499,000 after acquiring an additional 28,990 shares during the last quarter. Acadian Asset Management LLC grew its position in Surmodics by 11.3% in the 1st quarter. Acadian Asset Management LLC now owns 408,779 shares of the company's stock valued at $11,988,000 after acquiring an additional 41,617 shares during the last quarter. Gabelli Funds LLC lifted its holdings in Surmodics by 393.7% during the 2nd quarter. Gabelli Funds LLC now owns 260,200 shares of the company's stock valued at $10,939,000 after buying an additional 207,500 shares in the last quarter. Finally, Gardner Lewis Asset Management L P bought a new position in Surmodics in the second quarter worth approximately $8,531,000. 96.63% of the stock is currently owned by hedge funds and other institutional investors.
Surmodics Company Profile
(
Get Free Report)
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Further Reading
Before you consider Surmodics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surmodics wasn't on the list.
While Surmodics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
